These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

273 related items for PubMed ID: 32971253

  • 1. Effects of 13-valent pneumococcal conjugate vaccination of adults on lower respiratory tract infections and antibiotic use in primary care: secondary analysis of a double-blind randomized placebo-controlled study.
    van Werkhoven CH, Bolkenbaas M, Huijts SM, Verheij TJM, Bonten MJM.
    Clin Microbiol Infect; 2021 Jul; 27(7):995-999. PubMed ID: 32971253
    [Abstract] [Full Text] [Related]

  • 2. The impact of 13-valent pneumococcal conjugate vaccination on virus-associated community-acquired pneumonia in elderly: Exploratory analysis of the CAPiTA trial.
    Huijts SM, Coenjaerts FEJ, Bolkenbaas M, van Werkhoven CH, Grobbee DE, Bonten MJM, CAPiTA study team.
    Clin Microbiol Infect; 2018 Jul; 24(7):764-770. PubMed ID: 29050992
    [Abstract] [Full Text] [Related]

  • 3. Exploratory efficacy endpoints in the Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA).
    Webber C, Patton M, Patterson S, Schmoele-Thoma B, Huijts SM, Bonten MJ, CAPiTA Study Group.
    Vaccine; 2017 Mar 01; 35(9):1266-1272. PubMed ID: 28173960
    [Abstract] [Full Text] [Related]

  • 4. Incidence and Estimated Vaccine Effectiveness Against Hospitalizations for All-Cause Pneumonia Among Older US Adults Who Were Vaccinated and Not Vaccinated With 13-Valent Pneumococcal Conjugate Vaccine.
    Hsiao A, Hansen J, Timbol J, Lewis N, Isturiz R, Alexander-Parrish R, McLaughlin JM, Gessner BD, Klein NP.
    JAMA Netw Open; 2022 Mar 01; 5(3):e221111. PubMed ID: 35302634
    [Abstract] [Full Text] [Related]

  • 5. A post-hoc analysis of serotype-specific vaccine efficacy of 13-valent pneumococcal conjugate vaccine against clinical community acquired pneumonia from a randomized clinical trial in the Netherlands.
    Gessner BD, Jiang Q, Van Werkhoven CH, Sings HL, Webber C, Scott D, Gruber WC, Grobbee DE, Bonten MJM, Jodar L.
    Vaccine; 2019 Jul 09; 37(30):4147-4154. PubMed ID: 31155413
    [Abstract] [Full Text] [Related]

  • 6. Post-hoc analysis of a randomized controlled trial: Diabetes mellitus modifies the efficacy of the 13-valent pneumococcal conjugate vaccine in elderly.
    Huijts SM, van Werkhoven CH, Bolkenbaas M, Grobbee DE, Bonten MJM.
    Vaccine; 2017 Aug 03; 35(34):4444-4449. PubMed ID: 28410813
    [Abstract] [Full Text] [Related]

  • 7. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Medically Attended Lower Respiratory Tract Infection and Pneumonia Among Older Adults.
    Lewnard JA, Bruxvoort KJ, Fischer H, Hong VX, Grant LR, Jódar L, Cané A, Gessner BD, Tartof SY.
    Clin Infect Dis; 2022 Sep 14; 75(5):832-841. PubMed ID: 34967907
    [Abstract] [Full Text] [Related]

  • 8. The Community-Acquired Pneumonia immunization Trial in Adults (CAPiTA): what is the future of pneumococcal conjugate vaccination in elderly?
    van Werkhoven CH, Bonten MJ.
    Future Microbiol; 2015 Sep 14; 10(9):1405-13. PubMed ID: 26347153
    [Abstract] [Full Text] [Related]

  • 9. Post hoc analysis of the efficacy of the 13-valent pneumococcal conjugate vaccine against vaccine-type community-acquired pneumonia in at-risk older adults.
    Suaya JA, Jiang Q, Scott DA, Gruber WC, Webber C, Schmoele-Thoma B, Hall-Murray CK, Jodar L, Isturiz RE.
    Vaccine; 2018 Mar 07; 36(11):1477-1483. PubMed ID: 29429807
    [Abstract] [Full Text] [Related]

  • 10. Effectiveness of Pneumococcal Vaccination Against Pneumococcal Pneumonia Hospitalization in Older Adults: A Prospective, Test-Negative Study.
    Heo JY, Seo YB, Choi WS, Kim EJ, Jeong HW, Lee J, Yoon JG, Noh JY, Cheong HJ, Kim WJ, Song JY.
    J Infect Dis; 2022 Mar 02; 225(5):836-845. PubMed ID: 34537847
    [Abstract] [Full Text] [Related]

  • 11. Prevention of adult pneumococcal pneumonia with the 13-valent pneumococcal conjugate vaccine: CAPiTA, the community-acquired pneumonia immunization trial in adults.
    Isturiz R, Webber C.
    Hum Vaccin Immunother; 2015 Mar 02; 11(7):1825-7. PubMed ID: 26076136
    [Abstract] [Full Text] [Related]

  • 12. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults.
    Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, van Werkhoven CH, van Deursen AM, Sanders EA, Verheij TJ, Patton M, McDonough A, Moradoghli-Haftvani A, Smith H, Mellelieu T, Pride MW, Crowther G, Schmoele-Thoma B, Scott DA, Jansen KU, Lobatto R, Oosterman B, Visser N, Caspers E, Smorenburg A, Emini EA, Gruber WC, Grobbee DE.
    N Engl J Med; 2015 Mar 19; 372(12):1114-25. PubMed ID: 25785969
    [Abstract] [Full Text] [Related]

  • 13. Pneumococcus and the Elderly in Italy: A Summary of Available Evidence Regarding Carriage, Clinical Burden of Lower Respiratory Tract Infections and On-Field Effectiveness of PCV13 Vaccination.
    Orsi A, Ansaldi F, Trucchi C, Rosselli R, Icardi G.
    Int J Mol Sci; 2016 Jul 15; 17(7):. PubMed ID: 27428964
    [Abstract] [Full Text] [Related]

  • 14. Adult indication 13-valent pneumococcal conjugate vaccine clinical development overview: formulation, safety, immunogenicity (dosing and sequence), coadministration, and efficacy.
    Fletcher MA, Schmoele-Thoma B, Vojicic J, Daigle D, Paradiso PR, Del Carmen Morales G.
    Expert Rev Vaccines; 2024 Jul 15; 23(1):944-957. PubMed ID: 39279631
    [Abstract] [Full Text] [Related]

  • 15. Effectiveness of the 13-valent pneumococcal conjugate vaccine against adult pneumonia in Italy: a case-control study in a 2-year prospective cohort.
    Prato R, Fortunato F, Cappelli MG, Chironna M, Martinelli D.
    BMJ Open; 2018 Mar 25; 8(3):e019034. PubMed ID: 29581200
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of 13-Valent Pneumococcal Conjugate Vaccine Against Hospitalization for Community-Acquired Pneumonia in Older US Adults: A Test-Negative Design.
    McLaughlin JM, Jiang Q, Isturiz RE, Sings HL, Swerdlow DL, Gessner BD, Carrico RM, Peyrani P, Wiemken TL, Mattingly WA, Ramirez JA, Jodar L.
    Clin Infect Dis; 2018 Oct 30; 67(10):1498-1506. PubMed ID: 29790925
    [Abstract] [Full Text] [Related]

  • 17. Surveillance of pneumococcal serotypes in adults hospitalised with acute lower respiratory tract infection in Bristol, UK.
    Hyams C, Lahuerta M, Theilacker C, King J, Adegbite D, McGuinness S, Grimes C, Campling J, Southern J, Pride MW, Begier E, Maskell N, Oliver J, Jodar L, Gessner BD, Finn A, AvonCAP Research Group.
    Vaccine; 2024 Mar 07; 42(7):1599-1607. PubMed ID: 38336560
    [Abstract] [Full Text] [Related]

  • 18. Effectiveness of the 23-valent pneumococcal polysaccharide vaccine against vaccine serotype pneumococcal pneumonia in adults: A case-control test-negative design study.
    Lawrence H, Pick H, Baskaran V, Daniel P, Rodrigo C, Ashton D, Edwards-Pritchard RC, Sheppard C, Eletu SD, Litt D, Fry NK, Rose S, Trotter C, McKeever TM, Lim WS.
    PLoS Med; 2020 Oct 07; 17(10):e1003326. PubMed ID: 33095759
    [Abstract] [Full Text] [Related]

  • 19. Pneumococcal Conjugated Vaccine Reduces the High Mortality for Community-Acquired Pneumonia in the Elderly: an Italian Regional Experience.
    Baldo V, Cocchio S, Gallo T, Furlan P, Romor P, Bertoncello C, Buja A, Baldovin T.
    PLoS One; 2016 Oct 07; 11(11):e0166637. PubMed ID: 27846277
    [Abstract] [Full Text] [Related]

  • 20. Effectiveness of Pneumococcal Conjugate Vaccination Against Virus-Associated Lower Respiratory Tract Infection Among Adults: A Case-Control Study.
    Lewnard JA, Bruxvoort KJ, Hong VX, Grant LR, Jódar L, Cané A, Gessner BD, Tartof SY.
    J Infect Dis; 2023 Feb 14; 227(4):498-511. PubMed ID: 35323906
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 14.